AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy

Ann Tilton, Barry Russman, Resa Aydin, Umit Dincer, Raul G. Escobar, Sehim Kutlay, Zbigniew Lipczyk, Juan Carlos Velez, Anne Sophie Grandoulier, Anissa Tse, Philippe Picaut, Mauricio R. Delgado

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This secondary analysis of a large (n = 241), randomized, double-blind study evaluated the efficacy of 2 doses of abobotulinumtoxinA + standard of care (SOC) versus placebo + SOC in enabling children with dynamic equinus due to cerebral palsy to achieve their functional goals using Goal Attainment Scaling. Most parents/caregivers selected goals targeting aspects of gait improvement as most relevant. Mean (95% confidence interval) Goal Attainment Scaling T scores at week 4 were higher for both abobotulinumtoxinA groups versus placebo (treatment difference vs placebo: 10 U/kg/leg: 5.32 [2.31, 8.32], P = .0006, and 15 U/kg/leg 4.65 [1.59, 7.71], P = .0031). Superiority of both abobotulinumtoxinA doses versus placebo was maintained at week 12. Best goal attainment T scores were higher in the abobotulinumtoxinA groups versus placebo for the common goals of improved walking pattern, decreased falling, decreased tripping, and improved endurance. These findings demonstrate that single injections of abobotulinumtoxinA (10 and 15 U/kg/leg) significantly improved the ability of pediatric cerebral palsy patients to achieve their functional goals.

Original languageEnglish (US)
Pages (from-to)482-487
Number of pages6
JournalJournal of Child Neurology
Volume32
Issue number5
DOIs
StatePublished - 2017

Fingerprint

Cerebral Palsy
Placebos
Leg
Standard of Care
Accidental Falls
Aptitude
abobotulinumtoxinA
Gait
Double-Blind Method
Caregivers
Walking
Parents
Confidence Intervals
Pediatrics
Injections

Keywords

  • AbobotulinumtoxinA
  • Cerebral palsy
  • Dysport
  • Equinus foot
  • Goal attainment scaling

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. / Tilton, Ann; Russman, Barry; Aydin, Resa; Dincer, Umit; Escobar, Raul G.; Kutlay, Sehim; Lipczyk, Zbigniew; Velez, Juan Carlos; Grandoulier, Anne Sophie; Tse, Anissa; Picaut, Philippe; Delgado, Mauricio R.

In: Journal of Child Neurology, Vol. 32, No. 5, 2017, p. 482-487.

Research output: Contribution to journalArticle

Tilton, A, Russman, B, Aydin, R, Dincer, U, Escobar, RG, Kutlay, S, Lipczyk, Z, Velez, JC, Grandoulier, AS, Tse, A, Picaut, P & Delgado, MR 2017, 'AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy', Journal of Child Neurology, vol. 32, no. 5, pp. 482-487. https://doi.org/10.1177/0883073816686910
Tilton, Ann ; Russman, Barry ; Aydin, Resa ; Dincer, Umit ; Escobar, Raul G. ; Kutlay, Sehim ; Lipczyk, Zbigniew ; Velez, Juan Carlos ; Grandoulier, Anne Sophie ; Tse, Anissa ; Picaut, Philippe ; Delgado, Mauricio R. / AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. In: Journal of Child Neurology. 2017 ; Vol. 32, No. 5. pp. 482-487.
@article{13bc1a58f55d415a9f4fc74fb15d10d8,
title = "AbobotulinumtoxinA (Dysport{\circledR}) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy",
abstract = "This secondary analysis of a large (n = 241), randomized, double-blind study evaluated the efficacy of 2 doses of abobotulinumtoxinA + standard of care (SOC) versus placebo + SOC in enabling children with dynamic equinus due to cerebral palsy to achieve their functional goals using Goal Attainment Scaling. Most parents/caregivers selected goals targeting aspects of gait improvement as most relevant. Mean (95{\%} confidence interval) Goal Attainment Scaling T scores at week 4 were higher for both abobotulinumtoxinA groups versus placebo (treatment difference vs placebo: 10 U/kg/leg: 5.32 [2.31, 8.32], P = .0006, and 15 U/kg/leg 4.65 [1.59, 7.71], P = .0031). Superiority of both abobotulinumtoxinA doses versus placebo was maintained at week 12. Best goal attainment T scores were higher in the abobotulinumtoxinA groups versus placebo for the common goals of improved walking pattern, decreased falling, decreased tripping, and improved endurance. These findings demonstrate that single injections of abobotulinumtoxinA (10 and 15 U/kg/leg) significantly improved the ability of pediatric cerebral palsy patients to achieve their functional goals.",
keywords = "AbobotulinumtoxinA, Cerebral palsy, Dysport, Equinus foot, Goal attainment scaling",
author = "Ann Tilton and Barry Russman and Resa Aydin and Umit Dincer and Escobar, {Raul G.} and Sehim Kutlay and Zbigniew Lipczyk and Velez, {Juan Carlos} and Grandoulier, {Anne Sophie} and Anissa Tse and Philippe Picaut and Delgado, {Mauricio R.}",
year = "2017",
doi = "10.1177/0883073816686910",
language = "English (US)",
volume = "32",
pages = "482--487",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy

AU - Tilton, Ann

AU - Russman, Barry

AU - Aydin, Resa

AU - Dincer, Umit

AU - Escobar, Raul G.

AU - Kutlay, Sehim

AU - Lipczyk, Zbigniew

AU - Velez, Juan Carlos

AU - Grandoulier, Anne Sophie

AU - Tse, Anissa

AU - Picaut, Philippe

AU - Delgado, Mauricio R.

PY - 2017

Y1 - 2017

N2 - This secondary analysis of a large (n = 241), randomized, double-blind study evaluated the efficacy of 2 doses of abobotulinumtoxinA + standard of care (SOC) versus placebo + SOC in enabling children with dynamic equinus due to cerebral palsy to achieve their functional goals using Goal Attainment Scaling. Most parents/caregivers selected goals targeting aspects of gait improvement as most relevant. Mean (95% confidence interval) Goal Attainment Scaling T scores at week 4 were higher for both abobotulinumtoxinA groups versus placebo (treatment difference vs placebo: 10 U/kg/leg: 5.32 [2.31, 8.32], P = .0006, and 15 U/kg/leg 4.65 [1.59, 7.71], P = .0031). Superiority of both abobotulinumtoxinA doses versus placebo was maintained at week 12. Best goal attainment T scores were higher in the abobotulinumtoxinA groups versus placebo for the common goals of improved walking pattern, decreased falling, decreased tripping, and improved endurance. These findings demonstrate that single injections of abobotulinumtoxinA (10 and 15 U/kg/leg) significantly improved the ability of pediatric cerebral palsy patients to achieve their functional goals.

AB - This secondary analysis of a large (n = 241), randomized, double-blind study evaluated the efficacy of 2 doses of abobotulinumtoxinA + standard of care (SOC) versus placebo + SOC in enabling children with dynamic equinus due to cerebral palsy to achieve their functional goals using Goal Attainment Scaling. Most parents/caregivers selected goals targeting aspects of gait improvement as most relevant. Mean (95% confidence interval) Goal Attainment Scaling T scores at week 4 were higher for both abobotulinumtoxinA groups versus placebo (treatment difference vs placebo: 10 U/kg/leg: 5.32 [2.31, 8.32], P = .0006, and 15 U/kg/leg 4.65 [1.59, 7.71], P = .0031). Superiority of both abobotulinumtoxinA doses versus placebo was maintained at week 12. Best goal attainment T scores were higher in the abobotulinumtoxinA groups versus placebo for the common goals of improved walking pattern, decreased falling, decreased tripping, and improved endurance. These findings demonstrate that single injections of abobotulinumtoxinA (10 and 15 U/kg/leg) significantly improved the ability of pediatric cerebral palsy patients to achieve their functional goals.

KW - AbobotulinumtoxinA

KW - Cerebral palsy

KW - Dysport

KW - Equinus foot

KW - Goal attainment scaling

UR - http://www.scopus.com/inward/record.url?scp=85018169953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018169953&partnerID=8YFLogxK

U2 - 10.1177/0883073816686910

DO - 10.1177/0883073816686910

M3 - Article

VL - 32

SP - 482

EP - 487

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 5

ER -